News & Events

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need

First-line treatment patterns and real-world outcomes in patients with advanced KRAS-mutated non-small cell lung cancer with high unmet need

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutat

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutat

Clinical Trial: TCR1188-ABC Cells in KRAS-mutated Cancers

Clinical Trial: TCR1188-ABC Cells in KRAS-mutated Cancers

Bruna Pellini: Our New Manuscript Explores Sotorasib Plus T-DXd in KRAS G12C-Mutant NSCLC

Bruna Pellini: Our New Manuscript Explores Sotorasib Plus T-DXd in KRAS G12C-Mutant NSCLC

T-DXd Plus Sotorasib Shows Preclinical Promise in KRAS G12C-Mutant NSCLC

T-DXd Plus Sotorasib Shows Preclinical Promise in KRAS G12C-Mutant NSCLC

How Is Zoldonrasib Different From Other Therapies in KRAS G12D+ NSCLC?

How Is Zoldonrasib Different From Other Therapies in KRAS G12D+ NSCLC?

Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC

Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC